CompanyALGSNasdaqSouth San Francisco, CA

Aligos Therapeutics

Aligos Therapeutics develops therapies for liver and viral diseases, including treatments for chronic hepatitis B virus infection.

SEC EDGAR ClinicalTrials.gov aligos.com

8-KSep 15Latest SEC filing, period to Sep 10

Sep 15Latest story

September 2026

Aligos Therapeutics extends South San Francisco headquarters lease to 2034

Sep 15PartnershipAligos Therapeutics

August 2026

Aligos reports Q2 2026 results, pevifoscorvir sodium enrollment complete

Aug 6Quarterly updateAligos Therapeutics pevifoscorvir sodium

Aligos posts Phase 1 results for ALG-097558 in hepatic impairment study

Aug 5Trial updateALG-097558 Aligos Therapeutics

July 2026

Aligos posts results for ALG-097558 renal impairment PK study, trial completed

Jul 9Trial updateALG-097558 Aligos Therapeutics